Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ZBIO
ZENAS BIOPHARMA, INC.
NASDAQ
$31.27
▼ DOWN 4.14% (-1.35)

KEY STATISTICS

Market Cap$1.97 B
52w High$44.60
52w Low$13.50
Dividend Yield—
Frequency—
P/E-3.48
Volume439.13K
Shares Out.63.13M

COMPANY

LEADERSHIP

Leon Oliver Moulder Jr.
CHIEF EXECUTIVE
Leon Oliver Moulder Jr.

COMPENSATION 2026

Salary$520,000
Stock Awards$0
Incentive Plan Pay$371,800
All Other Comp.$0
Total$4,661,000

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 13, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
167

PRICE TARGET

Target High$32.00
Target Low$32.00
Target Median$32.00
Target Consensus$32.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$1.01M
NOV
12
THU

PRICE

$31.27 ▼ DOWN 4.14% (−$1.35)
$31.50$32.00$32.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM31.27

About Zenas BioPharma, Inc.

https://zenasbio.com ↗

Zenas BioPharma, Inc., a Waltham-based clinical-stage biopharma founded in 2019, develops immunology therapies like obexelimab and other monoclonal antibodies for autoimmune and inflammatory diseases.

INDUSTRY

Biotechnology

A PRODUCT ZENAS BIOPHARMA, INC. IS KNOWN FOR

Obexelimab
Obexelimab

Obexelimab, Zenas BioPharma’s lead bifunctional monoclonal antibody, is in late-stage trials for autoimmune diseases like IgG4-RD, with a BLA submission planned for the FDA in Q2 2026.

COMPETITORS

COMPETITOR
AMGN COMPARE
ARGX COMPARE
CABA COMPARE
KYTX COMPARE
TGTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
115
LISTED HERE
18
RANKED BY POSITION SIZE
XBI
0.39% · 1.4M
VTI
0.00% · 891.2K
XSU.TO
0.03% · 735.1K
SCHA
0.03% · 178.6K
SBIO
1.01% · 77.7K
LABU
0.27% · 52.3K
FESM
0.02% · 46.0K
XRS2.F
0.03% · 26.1K
PKW
0.04% · 24.4K
GSSC
0.07% · 22.9K
BBC
0.99% · 15.8K
RSSL
0.03% · 13.6K
BBSC
0.04% · 8.7K
DFAS
0.00% · 4.5K
BIB
0.07% · 2.3K
VETS
0.05% · 736
USFMDN.MX
0.00% · 124
RESM
0.04% · 69

INSTITUTIONAL OWNERSHIP

SHARES OWNED
65.90%
HOLDERS
183
TOP 12 OF 183 · RANKED BY POSITION SIZE
Fmr LLC
9.5M sh · $241.28M
Sr One Capital Management, LP
5.0M sh · $127.86M
Nea Management Company, LLC
4.0M sh · $78.65M
Enavate Sciences Gp, LLC
3.9M sh · $99.47M
Federated Hermes, Inc.
3.1M sh · $61.13M
Blackrock, Inc.
2.7M sh · $68.18M
Polar Capital Holdings Plc
2.5M sh · $49.82M
Capital International Investors
2.5M sh · $63.52M
Fairmount Funds Management LLC
2.4M sh · $46.12M
State Street Corp
2.1M sh · $52.16M
Novo Holdings A/S
2.0M sh · $44.4M
Nvp Associates, LLC
1.8M sh · $46.66M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: SEE REMARKS
Fox Jennifer A.
Purchase · 1.6K shares
2026-02-05
★
DIRECTOR
Nunn Jason Raleigh
Purchase · 18.5K shares
2026-06-15
★
DIRECTOR
Lu Hongbo
Purchase · 18.5K shares
2026-06-15
★
DIRECTOR, OFFICER: SEE REMARKS
MOULDER LEON O JR
Purchase · 500.0K shares
2026-06-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
EQUAL WEIGHT 1
OUTPERFORM 1
5 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY Morgan Stanley EQUAL WEIGHT Wedbush OUTPERFORM HC Wainwright & Co. BUY Citigroup BUY

SECTORS PEERS

PEERPRICE
RLAY$18.77COMPARE
AMLX$34.74COMPARE
TRVI$16.79COMPARE
INBX$123.41COMPARE
NTLA$12.87COMPARE
SNDX$19.54COMPARE
NVAX$9.26COMPARE
ORIC$13.24COMPARE